Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

Nigerians suffering from ailments caused by their consumption of sugar-sweetened beverages (SSBs) are spending billions of ...

Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan: Boston Friday, March 21, 2025, 16:00 Hrs [IST] Rhythm Pharmaceuticals, Inc ...

Rhythm Pharmaceuticals received an orphan-drug designation from Japan's Ministry of Health, Labour and Welfare for its treatment for a certain type of obesity.

Gandhinagar: Within a couple of days of making an announcement to launch a statewide campaign to sensitize citizens about ...

‘Overweight, including obesity, overtook tobacco use as the leading risk factor in 2024, driven by a substantial fall (41%) ...

Rhythm Pharmaceuticals (RYTM) announced it has received orphan drug designation from Japan’s Ministry of Health, Labour and Welfare for ...

Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothalamic obesity. Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity.

Lack of turnout and a dearth of owners with appropriate experience are among the drivers of the current equine welfare crisis ...

Having lost a great deal of weight appears to offer some protection against ill health even for those who have regained some ...